Merck looks to modest HIV business as a $5B underd
Post# of 156474

With Keytruda's patent cliff looming. (2027) I believe...
Merck has to to find WAYS to shore up its business, and it is betting that HIV will be one of those that assist in that endeavor.
Speaking of connecting the dots...don't We have a kind of HIV drug...underdog???

